Dr. Lal PathLabs Invests ₹30.3 Cr in Subsidiary PUPL

Dr. Lal PathLabs Ltd has made a further investment in its wholly-owned subsidiary, PathLabs Unifiers Private Limited (PUPL), by subscribing to equity shares for a cash consideration not exceeding ₹30.3 Crores. This investment is intended to fund PUPL's acquisition of the remaining 30% equity stake in CentraPath Labs Private Limited (CPL). Post this transaction, CPL will become a wholly-owned subsidiary of PUPL. PUPL's turnover for FY26 was ₹7.23 Crores, FY25 was ₹7.10 Crores, and FY24 was ₹7.28 Crores. The transaction is considered a related party transaction on an arm's length basis.